BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Valeant Pharmaceuticals International (VRX) Shuts Down One Plant, More to Follow


1/10/2013 8:04:32 AM

Canadian firm Valeant Pharmaceuticals has closed down one of its facilities in Brazil and will shutter a second in the first half of this year as it trims down its manufacturing network. The plants were inherited by Valeant as part of its acquisition of Brazilian branded generic and over-the-counter medicines company Probiotica Laboratorios last year in a 150 million real ($85 million) deal. A second facility in Brazil will be closed by the end of the first half of 2013, leaving the company with one remaining plant in the country, said Valeant chairman and chief executive Michael Pearson in a conference call with analysts last week. The company's Bourdon plant in Canada is also set for closure and the company said recently it would terminate a collaboration with a Puerto Rican contract manufacturer as it continues to consolidate its production capacity. Towards the end of 2012 Valeant closed its $2.6 billion acquisition of dermatology specialist Medicis Pharmaceuticals, but Pearson said on the conference call that this would not provide any additional opportunities for facility consolidation as Medicis has relied on contract manufacturers to make its products.

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES